What development phase is LUPROSTIOL in?

LUPROSTIOL is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

LUPROSTIOL

FDA-approved active Small molecule Quality 6/100

LUPROSTIOL is a marketed drug that interacts with a specific biological target to address its primary indication. The key composition patent for LUPROSTIOL is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk facing LUPROSTIOL is the loss of exclusivity post-2028, which could significantly impact its market position.

At a glance

Generic name	LUPROSTIOL
Modality	Small molecule
Therapeutic area	Immunology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LUPROSTIOL CI brief — competitive landscape report
LUPROSTIOL updates RSS · CI watch RSS